Glucagon receptor and mitochondrial complex I (NADH:ubiquinone oxidoreductase) (GCGR and Complex I)

This target refers to the integrated signaling axis involving the glucagon receptor (GCGR) and the mitochondrial respiratory chain complex I (NADH:ubiquinone oxidoreductase). The interaction between these two components is central to the glucose-lowering mechanism of biguanides like metformin (Miller et al., 2013). Specifically, mild inhibition of mitochondrial complex I reduces cellular energy charge, increasing the intracellular AMP:ATP ratio (Madiraju et al., 2014). This elevation in AMP directly inhibits adenylate cyclase, the enzyme responsible for generating cyclic AMP (cAMP) upon glucagon receptor activation. By disrupting this signaling cascade, the pathway suppresses glucagon-stimulated hepatic gluconeogenesis and glycogenolysis, effectively lowering blood glucose levels in patients with type 2 diabetes (LaMoia & Shulman, 2021). This dual-component target represents a critical node in metabolic regulation and a primary site for pharmacological intervention in metabolic diseases such as obesity and non-alcoholic fatty liver disease. While the glucagon receptor is a G protein-coupled receptor located on the cell membrane, mitochondrial complex I is an enzyme complex within the inner mitochondrial membrane, and their functional link is mediated by cellular energy metabolites. Understanding this interaction has provided new insights into how existing therapies work and has opened avenues for developing more specific metabolic modulators.

Other names

Glucagon receptor-mitochondrial complex I axisMetformin-mediated glucagon antagonismGCGR-Complex I interactionHepatic glucagon signaling and mitochondrial respiratory chain interaction

Inhibition of mitochondrial complex I leads to an increased intracellular AMP:ATP ratio, which inhibits adenylate cyclase and prevents glucagon receptor-mediated cyclic AMP (cAMP) production, thereby suppressing hepatic gluconeogenesis.